CN102573856B - 用于制备微小rna 的方法及其治疗性应用 - Google Patents

用于制备微小rna 的方法及其治疗性应用 Download PDF

Info

Publication number
CN102573856B
CN102573856B CN201080046930.0A CN201080046930A CN102573856B CN 102573856 B CN102573856 B CN 102573856B CN 201080046930 A CN201080046930 A CN 201080046930A CN 102573856 B CN102573856 B CN 102573856B
Authority
CN
China
Prior art keywords
hsa
mir
body fluid
mirna
described body
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080046930.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102573856A (zh
Inventor
弗莱明·韦林
斯文·林登堡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42147287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102573856(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CN102573856A publication Critical patent/CN102573856A/zh
Application granted granted Critical
Publication of CN102573856B publication Critical patent/CN102573856B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
CN201080046930.0A 2009-09-10 2010-09-10 用于制备微小rna 的方法及其治疗性应用 Expired - Fee Related CN102573856B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09169937.1 2009-09-10
EP09169937 2009-09-10
PCT/EP2010/063313 WO2011029903A1 (en) 2009-09-10 2010-09-10 Method for the preparation of micro-rna and its therapeutic application

Publications (2)

Publication Number Publication Date
CN102573856A CN102573856A (zh) 2012-07-11
CN102573856B true CN102573856B (zh) 2016-10-26

Family

ID=42147287

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080046930.0A Expired - Fee Related CN102573856B (zh) 2009-09-10 2010-09-10 用于制备微小rna 的方法及其治疗性应用

Country Status (8)

Country Link
US (1) US9078914B2 (enExample)
EP (1) EP2475372B2 (enExample)
JP (1) JP5902088B2 (enExample)
CN (1) CN102573856B (enExample)
AU (1) AU2010294197C9 (enExample)
CA (1) CA2773619C (enExample)
DK (1) DK2475372T4 (enExample)
WO (1) WO2011029903A1 (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
AU2010294197C9 (en) 2009-09-10 2018-09-13 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
CA2801342A1 (en) 2010-06-04 2011-12-08 Eric N. Olson Regulation of metabolism by mir-378
US10385314B2 (en) * 2010-08-16 2019-08-20 Exostem Biotec Ltd. Methods of generating oligodendrocytes and cell populations comprising same
AR084319A1 (es) 2010-12-15 2013-05-08 Miragen Therapeutics INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
US9771617B2 (en) 2011-06-27 2017-09-26 Eisai R&D Management Co., Ltd. Microrna biomarkers indicative of alzheimer's disease
CN102296112B (zh) * 2011-08-09 2013-06-05 南京医科大学 人类非梗阻性无精子症相关的精浆微小核糖核酸标志物及其应用
EP2742148B1 (en) * 2011-08-11 2017-06-28 Hummingbird Diagnostics GmbH Complex sets of mirnas as non-invasive biomarkers for psoriasis
US20140302068A1 (en) * 2011-09-09 2014-10-09 The Regents Of The University Of Colorado MicroRNA Biomarkers for Diagnosing Parkinson's Disease
CA2850223A1 (en) 2011-10-06 2013-04-11 Eva Van Rooij Control of whole body energy homeostasis by microrna regulation
ES2967272T3 (es) * 2011-11-30 2024-04-29 Bullerdiek Joern Expresión de miARNs en tejido placentario
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
US9334498B2 (en) 2012-05-10 2016-05-10 Uab Research Foundation Methods and compositions for modulating MIR-204 activity
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
CN102727909B (zh) * 2012-06-28 2014-06-04 中国人民解放军总医院 一种抑制原发性肝癌生长和转移的新方法
CN102787117A (zh) * 2012-07-20 2012-11-21 苏州大学 微小rna用于调控b7-h2基因表达
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
CN103667282A (zh) * 2012-08-30 2014-03-26 苏州博泰安生物科技有限公司 前列腺癌分子标志物miR-628-3P及其应用
WO2014072468A1 (en) * 2012-11-09 2014-05-15 Velin-Pharma A/S Compositions for pulmonary delivery
WO2014086243A1 (zh) * 2012-12-07 2014-06-12 中国科学院上海生命科学研究院 负向调控I型干扰素通路的miRNA分子及其应用
CN103173448A (zh) * 2013-02-07 2013-06-26 上海市胸科医院 早期肺腺癌miRNA特异表达谱及其反转录引物和用途
WO2014152932A1 (en) * 2013-03-14 2014-09-25 Board Of Regents, The University Of Texas System Mirna for treating cancer and for use with adoptive immunotherapies
US20160017326A1 (en) * 2013-03-14 2016-01-21 The Trustees Of Princeton University Micrornas as functional mediators and biomarkers of bone metastasis
CN103961720B (zh) * 2013-03-19 2016-03-02 广州中国科学院先进技术研究所 MicroRNA用于制备降低神经胶质瘤对TRAIL耐受性的药物的用途
JP6137894B2 (ja) * 2013-03-22 2017-05-31 国立大学法人京都大学 リポソーム−エキソソームハイブリッドベシクル及びその調製法
CN103194542B (zh) * 2013-04-28 2014-03-26 夏彦恺 人类胎儿生长受限相关的血清微小核糖核酸标志物及其应用
CN103205430B (zh) * 2013-04-28 2015-04-15 夏彦恺 人类重度子痫前期发生相关的血清微小核糖核酸标志物及其应用
WO2014189850A1 (en) 2013-05-20 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Detection and treatment of irritable bowel syndrome
WO2015026611A1 (en) 2013-08-20 2015-02-26 The Board Of Regents Of The University Of Texas System Micro-rna regulation of bone loss
CN105899238B (zh) * 2013-09-20 2021-02-26 中央研究院 通过调节微RNAmiR-130a、miR-130b、miR-204或miR-1236治疗肝炎病毒感染
WO2015073531A1 (en) * 2013-11-13 2015-05-21 The Texas A & M University System Micro-rnas that modulate lymphangiogenesis and inflammatory pathways in lymphatic vessel cells
WO2015081263A1 (en) 2013-11-26 2015-06-04 Central Biomedia, Inc. Method and diet for immune enhanced donor blood
CN103623431B (zh) * 2013-12-05 2015-04-22 南京大学 miR181s在制备治疗急性肠炎药物中的应用
RU2548816C1 (ru) * 2013-12-16 2015-04-20 Мамонтова Марина Васильевна Способ выделения микрорнк из биологических жидкостей
WO2015091892A1 (en) * 2013-12-19 2015-06-25 Comprehensive Biomarker Center Gmbh Mirnas as non-invasive biomarkers for parkinson's disease
JP6353073B2 (ja) 2013-12-20 2018-07-04 アドヴァンスド リジェン メディカル テクノロジーズ，エルエルシー 細胞回復のための組成物並びにその作製及び使用方法
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
SI3119437T1 (sl) 2014-03-21 2020-01-31 Genzyme Corporation Genska terapija za retinitis pigmentoza
KR101667650B1 (ko) * 2014-03-31 2016-10-20 숙명여자대학교산학협력단 ｍｉＲ-192, ｍｉＲ-215 또는 ｍｉＲ-194를 포함하는 인간 상염색체 우성 다낭신 치료용 약학 조성물
CN103937826B (zh) * 2014-04-04 2016-04-06 东华大学 一种中枢神经系统中特异表达miR-505的载体的制备方法
US10125398B2 (en) * 2014-06-13 2018-11-13 Universitat Fur Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
JP6566612B2 (ja) * 2014-06-27 2019-08-28 国立大学法人北海道大学 免疫体質又は免疫応答型を判定するためのバイオマーカー及び免疫応答型制御剤
JP6385732B2 (ja) * 2014-06-27 2018-09-05 国立大学法人北海道大学 免疫応答制御剤
CN105368822A (zh) * 2014-08-29 2016-03-02 香港大学 一种miRNA标记物、其方法和应用
CN105457039A (zh) * 2014-09-10 2016-04-06 洪挺祯 促进伤口愈合的制剂及其制备方法及使用方法
CN104306988B (zh) * 2014-09-25 2017-02-15 中国医学科学院基础医学研究所 miR‑431在制备治疗肌肉疾病的药物中的用途
JP6878274B2 (ja) 2014-10-03 2021-05-26 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム
CN104491878A (zh) * 2014-12-19 2015-04-08 青岛大学 一种含有miRNA-324的药物组合物及其用途
JP2018503646A (ja) 2015-01-20 2018-02-08 ミラゲン セラピューティクス， インコーポレイテッド ｍｉＲ−９２阻害剤およびその使用
CN104830858A (zh) * 2015-03-05 2015-08-12 中国人民解放军第四军医大学 一种与浆液性卵巢癌发生发展机制相关的microRNA分子及其应用
CN105647919A (zh) * 2015-04-01 2016-06-08 四川大学华西医院 一种microRNA-129-5p的检测试剂盒和检测方法
CN104940954B (zh) * 2015-06-23 2017-12-26 同济大学 MicroRNA‑7在制备抗胶质化药物中的应用
US10441601B2 (en) 2015-06-30 2019-10-15 St. Jude Children's Research Hospital, Inc. Method for treating schizophrenia
HK1254594A1 (zh) * 2015-07-02 2019-07-26 University Of Louisville Research Foundation, Inc. 用於递送mirna的源自可食用植物的微囊泡组合物和用於治疗癌症的方法
CN105497915A (zh) * 2015-07-21 2016-04-20 青岛大学附属医院 miR-223-3p或miR-885-5p模拟物在制备治疗急性痛风性关节炎药物中的应用
CN105363042B (zh) * 2015-10-21 2022-05-06 圣诺生物医药技术(苏州)有限公司 一种药物组合物及其应用
CN105288658B (zh) * 2015-10-30 2018-08-28 中国人民解放军第三军医大学 miR-18a-5p抑制剂在制备防治骨质疏松药物中的应用
WO2017078099A1 (ja) 2015-11-06 2017-05-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP6841040B2 (ja) 2015-12-10 2021-03-10 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11266672B2 (en) 2016-01-28 2022-03-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN105854017A (zh) * 2016-03-01 2016-08-17 扬州大学 一种治疗β-地中海贫血的试剂及其应用
BR112018072198A2 (pt) * 2016-04-29 2019-02-12 Advanced ReGen Medical Technologies, LLC composição compreendendo micrornas, método de preparação de uma composição de célula-tronco restaurada, formulação farmacêutica e kit
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
JP6984415B2 (ja) 2016-08-09 2021-12-22 東レ株式会社 癌の治療用及び／又は予防用医薬組成物
IT201600093825A1 (it) * 2016-09-19 2018-03-19 Fondazione St Italiano Tecnologia Composizione farmaceutica di miRNA e suoi usi terapeutici.
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
WO2018139759A1 (ko) * 2017-01-26 2018-08-02 주식회사 바이오오케스트라 마이크로 rna를 이용한 알츠하이머병 진단방법
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
WO2018208969A1 (en) * 2017-05-09 2018-11-15 New York University Micrornas for treatment of neuropathic pain
CN107412250B (zh) * 2017-05-11 2019-03-05 南京北恒生物科技有限公司 miR-193a-3p的应用
WO2018205978A1 (zh) * 2017-05-11 2018-11-15 北京捷腾生物科技有限公司 预防口腔癌的方法
CN107287319B (zh) * 2017-07-13 2021-07-02 青岛大学 miRNA-485-5p核苷酸类似物及其反义核苷酸的应用和应用其的产品
KR101956315B1 (ko) 2017-07-19 2019-03-08 국민대학교 산학협력단 파킨슨병 바이오마커로서의 miR494 및 이를 이용한 진단키트
CN107419022B (zh) * 2017-08-17 2021-03-16 武汉大学 与绝经后骨质疏松相关的miRNA标志物和试剂盒
CN107693535A (zh) * 2017-09-05 2018-02-16 上海市光华中西医结合医院 一种microRNA的应用
CN109722473A (zh) * 2017-10-31 2019-05-07 中国科学院深圳先进技术研究院 与骨代谢疾病相关的miRNA标志物miR-19b的应用
WO2019103300A1 (ko) * 2017-11-27 2019-05-31 (주)프로스테믹스 Mirna를 포함하는 상처 치료 또는 피부 개선용 조성물
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE
US10717981B2 (en) 2018-01-18 2020-07-21 Advanced ReGen Medical Technologies, LLC Therapeutic compositions and methods of making and using the same
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
CN108853132A (zh) * 2018-05-22 2018-11-23 深圳先进技术研究院 一种miR-340调控IL-17A表达的用途
EP3820483A4 (en) * 2018-07-13 2023-03-01 Yale University COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS
AU2019319623A1 (en) 2018-08-08 2021-02-25 Theramir Ltd Microrna-based therapy targeted against LCP-1 positive cancers
CN110038026B (zh) * 2019-03-27 2021-08-17 浙江大学 mmu-miR-218-5p在制备抑制胚胎着床的药物中的应用
CN110075122B (zh) * 2019-05-09 2021-04-20 复旦大学附属中山医院 一种肝癌治疗性外泌体药物
US11198908B2 (en) 2019-06-17 2021-12-14 Biorchestra Co., Ltd. Method for diagnosis of Alzheimer's disease using microRNA
MX2022000074A (es) * 2019-07-02 2022-04-06 Ohio State Innovation Foundation Terapias para enfermedades neurodegenerativas que usan el eje piel cerebro.
KR102323535B1 (ko) * 2019-07-10 2021-11-08 주식회사 엠디헬스케어 당뇨병성 신증 진단용 조성물
IT201900017234A1 (it) * 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
CN110791560B (zh) * 2019-11-06 2021-09-14 中国医学科学院医药生物技术研究所 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
US20220409652A1 (en) * 2019-11-29 2022-12-29 Novadip Biosciences miRNA-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND THE TREATMENT OF TISSUE DISORDERS
CN111330008B (zh) * 2020-02-11 2021-02-05 四川大学 miR-93抑制剂在制备修复牙本质的药物中的用途
CN111529713B (zh) * 2020-05-11 2021-10-22 山东大学 一种AuNPs/miR-140复合物及其制备方法和应用
CN111840310B (zh) * 2020-07-27 2021-11-26 中国农业科学院兰州兽医研究所 ssc-miR-151-3p在制备调节猪繁殖与呼吸综合征病毒复制的药物中的应用
KR102371833B1 (ko) * 2020-09-14 2022-03-08 서울대학교산학협력단 GDF11 유전자의 발현을 조절하는 microRNA 및 이를 함유하는 조성물
CN112410414B (zh) * 2020-10-09 2022-07-08 嘉兴市妇幼保健院 孕妇血清外泌体miRNA标志物在制备胎儿先心病早期诊断产品中的应用及试剂盒
CN112359040B (zh) * 2020-11-02 2021-09-14 广东省科学院动物研究所 调节let-7基因表达量的制剂在制备调节蜜蜂糖反应性行为制剂中的应用
CN112402440A (zh) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 miR-325核酸类似物在制备治疗血窦内皮细胞病理性功能异常相关产品中的应用
CN112458165A (zh) * 2020-12-27 2021-03-09 中山大学孙逸仙纪念医院 一种阿尔茨海默病的预测标志物、检测试剂盒及应用
CN114438187B (zh) * 2021-01-29 2022-08-26 浙江大学医学院附属妇产科医院 一种诊断早期流产的miRNA标志物及其应用
CN114214328A (zh) * 2021-12-17 2022-03-22 川北医学院附属医院 一种核酸药物及其应用
EP4581142A1 (en) 2022-09-02 2025-07-09 Leibniz-Institut für Immuntherapie (LIT) Therapeutic use of the mir155 snp rs377265631
WO2025054607A1 (en) * 2023-09-07 2025-03-13 The Regents Of The University Of California Compositions and methods for treating sarcopenia
CN117257822B (zh) * 2023-09-23 2025-10-28 广州四叶草健康科技有限公司 一种治疗阿尔兹海默病的外泌体混合液及其制备方法
CN117683883B (zh) * 2024-01-11 2024-12-20 山东中医药大学 miR-126-5p在不明原因复发性自然流产诊治中的应用
CN118105400B (zh) * 2024-03-14 2024-08-20 南京市妇幼保健院 一种人子宫内膜间充质干细胞外泌体来源的微小RNA miR-30b及其应用
CN119040464B (zh) * 2024-10-16 2025-04-18 合肥工业大学 一种口腔鳞状细胞癌诊断生物标志物hsa-miR-331-3p及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378768A (zh) * 2006-02-03 2009-03-04 奥尔托金股份有限公司 调整的血液成分及制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US622690A (en) 1899-04-11 howell
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5707331A (en) 1995-05-05 1998-01-13 John R. Wells Automatic multiple-decanting centrifuge
CA2301174C (en) 1997-08-16 2007-11-27 Orthogen Gentechnologie Gmbh A method for inducing therapeutically-effective proteins
DE19903876B4 (de) † 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
EP1093390B1 (en) 1999-04-12 2013-05-08 Harvest Technologies Corporation Method and apparatus for producing platelet rich plasma and/or platelet concentrate
JP2002174633A (ja) * 2000-12-08 2002-06-21 Erc:Kk 血清の保存方法
DE10213780A1 (de) * 2002-03-22 2003-11-27 Orthogen Ag Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
JP4233525B2 (ja) 2002-09-19 2009-03-04 ハーベスト・テクノロジーズ・コーポレイション 使い捨て可能な無菌処理ユニット
WO2004104553A2 (en) 2003-05-19 2004-12-02 Harvest Technologies Corporation Method and apparatus for separating fluid components
JP2008505104A (ja) 2004-07-01 2008-02-21 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 免疫抑制性エキソソーム
EP1797183B1 (en) 2004-09-02 2012-08-01 Yale University Regulation of oncogenes by micrornas
US20100298407A1 (en) 2007-01-17 2010-11-25 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
JP2008182921A (ja) 2007-01-29 2008-08-14 Osaka Univ 磁性粒子を用いた遺伝子導入方法
WO2008095096A2 (en) * 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
WO2008097230A1 (en) 2007-02-09 2008-08-14 Harvest Technologies Corporation Tissue graft composition comprising autologous bone marrow and purified autologous thrombin
US8288358B2 (en) * 2007-03-26 2012-10-16 Newcastle Innovation Ltd. Therapeutic targets and molecules
US20090124566A1 (en) * 2007-06-07 2009-05-14 Duke University Methods and compositions for the treatment of erythrocyte diseases
JP5399011B2 (ja) * 2007-06-28 2014-01-29 三菱化学メディエンス株式会社 組織傷害あるいは細胞増殖性疾患の検出方法
WO2009021325A1 (en) * 2007-08-10 2009-02-19 British Columbia Cancer Agency Branch Microrna compositions and methods for the treatment of myelogenous leukemia
EP2183393B1 (en) 2007-09-06 2014-06-11 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
US20090136942A1 (en) * 2007-09-18 2009-05-28 Oncomedx, Inc. Analysis of Extracellular RNA
AU2008329755A1 (en) 2007-11-30 2009-06-04 The Ohio State University Research Foundation MicroRNA expression profiling and targeting in peripheral blood in lung cancer
WO2009104051A2 (en) * 2007-12-31 2009-08-27 Lu Patrick Y Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and rnai medicine
PL2254586T3 (pl) 2008-02-22 2015-09-30 Agency For Science Tech And Research Astarstar Cząstki mezenchymalnych komórek macierzystych
WO2009143379A2 (en) * 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
WO2010118979A1 (en) 2009-04-07 2010-10-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
AU2010294197C9 (en) 2009-09-10 2018-09-13 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101378768A (zh) * 2006-02-03 2009-03-04 奥尔托金股份有限公司 调整的血液成分及制备方法

Also Published As

Publication number Publication date
DK2475372T4 (da) 2020-11-30
WO2011029903A1 (en) 2011-03-17
DK2475372T3 (en) 2017-10-23
CN102573856A (zh) 2012-07-11
CA2773619C (en) 2019-11-12
CA2773619A1 (en) 2011-03-17
AU2010294197C1 (en) 2018-08-02
US20120172416A1 (en) 2012-07-05
AU2010294197B2 (en) 2015-08-20
AU2010294197C9 (en) 2018-09-13
JP2013504542A (ja) 2013-02-07
EP2475372B2 (en) 2020-10-21
JP5902088B2 (ja) 2016-04-13
EP2475372B1 (en) 2017-07-05
US9078914B2 (en) 2015-07-14
AU2010294197A1 (en) 2012-03-22
EP2475372A1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
CN102573856B (zh) 用于制备微小rna 的方法及其治疗性应用
EP2416789B1 (en) Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
US10876119B2 (en) Reduced size self-delivering RNAI compounds
EP2916853B1 (en) Compositions for pulmonary delivery
US10526602B2 (en) Segmented micro RNA mimetics
US11602568B2 (en) Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
JP6035010B2 (ja) マイクロｍｉｒ
US20140080894A1 (en) Enhanced biodistribution of oligomers
US20110152352A1 (en) Smad proteins control drosha-mediated mirna maturation
US20180237772A1 (en) HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE
US20190338314A1 (en) Exosome Delivery System
Chiu et al. MicroRNA mediation of endothelial inflammatory response to smooth muscle cells and its inhibition by atheroprotective shear stress

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161026

CF01 Termination of patent right due to non-payment of annual fee